Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJZ48W)

• Drug Name: AHR-16303B Drug Info
• Synonyms: Ahr-16303B; Ahr 16303B; 117023-62-8; 1-(4-(3-(4-(Bis-(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-1-propanone ethanedioate; ACMC-20mmz9; AC1L4DL2; CTK0H5536; DTXSID80151685; 1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]phenyl]-2-methylpropan-1-one; 1-Propanone, 1-(4-(3-(4-(bis(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-, ethanedioate (1:1) (salt)

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 183770
  CAS Number: CAS 117023-62-8
  TTD Drug ID: DMJZ48W

Molecule-Related Drug Atlas

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[2]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[3]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[4]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[5]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[6]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[7]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[7]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[8]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[9]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[10]

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[11]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[12]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[13]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[14]
Bis(olanzapine) pamoate monohydrate	DME76AP	Psychotic disorder	6A20-6A25	Phase 3	[15]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[16]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[17]
TGWOOAA	DMI57ZA	Generalized anxiety disorder	6B00	Phase 2	[18]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[19]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Modulator	[1]
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[1]

References

• [1] AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
• [2] Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
• [3] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [4] RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
• [5] Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
• [6] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [11] 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
• [12] Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
• [13] Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
• [14] Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [18] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [19] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [20] Clinical pipeline report, company report or official report of Anamar.